Company*
(Country; Symbol)

University/ Nonprofit@

Type Of  Agreement

Product Area

Details (Date)


Acacia Research
Corp.
(ACTG)

The Centre for Applied Genomics (Canada)

Partnership

To gain access to the consortium's published markers for autism

Acacia's division CombiMatrix Molecular Diagnostics plans to use them in upcoming versions of its Constitutional Genetic Array Test (3/7)

 

Advanced Cell
Technology Inc.
(OTC BB:ACTC)

Casey Eye Institute at Oregon Health and Science University

Sponsored research agreement

To conduct preclinical studies for its retinal pigment epithelium program

The research team is conducting a dosage study using the company's RPE cells in a rat model and plans to conduct similar studies in other rodent models of retinal degenerativedisease (2/6)

 

Affymetrix
Inc.
(AFFX)

Baylor College of Medicine

License agreement

Baylor got rights to Affymetrix patents covering comparative genomic hybridization microarray services

The nonexclusive license covers services in Clinical Laboratory Improvement Amendments environments; terms of the deal were not disclosed (12/5)

 

Affymetrix
Inc.
(AFFX)

Vanderbilt- Ingram Cancer Center

Translational research collaboration 

Three-year agreement to analyze genomic information across a large number of  patient samples

Researchers will use Affymetrix GeneChip microarray technol- ogy to develop new applications for translational research (1/24)

 

Aruna
Biomedical
Inc.*

University of Georgia Research Foundation

License agreement

Agreement to develop and commercialize neural cells derived from human embryonic stem cells

Aruna will offer researchers access to human neural cells that relate to normal and diseased conditions (1/26)

 

Asuragen Inc.*

Yale University

License agreement

For exclusive access to rights in inventions developed by Frank Slack for the regulation of oncogenes by microRNAs

A collaboration revealed that  human let-7 regulates the expression of ras and that misregulation of let-7 in human lung cells likely contributes to  the development of lung cancer via altered expression of ras (1/10)

 

AVAX
Technologies
Inc.
(OTC BB:AVXT)

Cancer Treatment Centers of America

Agreement

Focused on AVAX's O-Vax therapeutic for ovarian cancer  and CTCA's activated natural killer cell technology for various human cancers

AVAX will receive more than $1M in research and development funding (2/21)

 

Avicena
Group Inc.
(OTC BB:AVGO)

National Institute of Neurological Disorders and Stroke

Agreement

Avicena will supply PD-02 for a Phase III trial that is being planned by NINDS

PD-02 is a neuroprotective agent Avicena is developing for Parkin- son's disease; it gets rights to use the study's findings (12/6)

 

Bio-Bridge
Sciences Inc.
(OTC BB:BGES)

Chinese Academy of Medical Sciences

Cooperative agreement

To develop a human papillomavirus vaccine expected to provide broader  protection than Gardasil with lower production costs

Bio-Bridge has assumed 60% interest in the project and will receive preferential rights to develop the vaccine (3/9)

 

BioCurex
Inc.
(Canada;
OTC BB:BOCX)

Blokhin Cancer Research Center (Russia)

Collaboration

Deal to further develop and evaluate BioCurex's RECAF technology

The RECAF marker will be tested  in cancer screening, diagnosis and follow-up of treated patients (12/7)

 

BioE Inc.*

University of Texas M.D. Anderson Cancer Center

Research partnership

To evaluate the  potential of BioE's cord blood stem cell,  the Multi-Lineage Progenitor Cell, to  help treat cancer

Researchers will study the technology's utility as an antitumor protein delivery vehicle (1/29)

 

BioNanomatrix
LLC*

Radiation Biology Branch at the National Cancer Institute

CRADA

Agreement to use BioNanomatrix's whole-genome analyzer to develop methods to detect, identify and quantify DNA damage caused by ionizing radiation

The initial focus is on assessing radiation-induced damage to DNA (1/18)

 

BioServe
Biotechnologies
Ltd.*

Harvard University and the University of Michigan

Agreement

BioServe will perform DNA purification and genotyping on tissue samples collected  from 750 school children in Chennai,  India, who have been exposed to lead pollutants

The effort is part of a study by the universities on how genetics and environmental lead pollution interact to affect children's intellectual and behavioral functioning (1/24)

 

Biotage AB
(Sweden;
SSE:BIOTA)

McMaster University
(Canada)

Agreement

To develop a new chemistry platform to speed the production of molecular imaging and therapy agents

Biotage will provide funding and instruments (2/26)

 

BioTrove Inc.*

Stanford University Genome Technology Center

License

Stanford will use the BioTrove OpenArray technology platform to advance its multiple research projects

Applications are expected in single nucleotide polymorphism genotyping, real-time quantitative polymerase chain reaction-based tests, and the development of novel uses for the Open-Array system(2/27)

 

Cepheid Inc.
(CPHD)

Idaho Technology Inc.

Settlement and cross- license agreement

To resolve a dispute related to the intellectual property in  rapid polymerase chain reaction methods and instrumentation, the use of SYBR Green I  in PCR reactions and certain methods of analysis of real-time PCR data

The settlement resolves all claims from a lawsuit started in 2005 by Idaho Technology and its licensor, University of Utah Research Foundation; Cepheid made a one- time payment to Idaho of $3.35 million (1/11)

 

Champions
Biotechnology
Inc.
(OTC BB:CSBR)

Johns Hopkins University

Patent rights agreement

For patents encompassing two benzoylpheny-lura sulfura analogue compounds that have shown activity against prostate and pancreatic cancer cell lines

The antimitotic inhibitors target microtubule-associated protein tau-deficient tumors; rights were exchange for 550,000 restricted shares of common stock (2/14)

 

Cleveland
BioLabs Inc.
(CBLI)

Roswell Park Cancer Institute

Partnership

To develop the company's cancer and  radioprotectant drug candidates

Roswell Park and other New York agencies will provide the company with up to $5 million and Cleveland BioLabs will establish a research facility at the Roswell Park campus (1/12)

 

Copernicus
Therapeutics Inc.*

Cystic Fibrosis Foundation Therapeutics Inc.

Agreement

To support continued development of a gene therapy for cystic fibrosis

Copernicus will receive up to $5.2M in funding (2/15)

 

DiaDexus Inc.*

Mayo Validation Support Services (affiliate of the Mayo Clinic)

Collaboration

To investigate a test featuring a select panel of tumor-specific genes

The test will aid in patient risk stratification and assist in chemotherapy treatment decisions for breast cancer patients (1/10)

 

Dyadic
International
Inc.
(AMEX:DIL)

Royal Nedalco (the Netherlands)

Research and development project

Dyadic joined others in a project sponsored by the Netherlands government to develop technologies of ethanol production from sugar beet pulp and wheat bran

Dyadic Nederland BV, the company's subsidiary in Zeist, the Netherlands, will focus on the development of optimal enzyme preparation for the extraction of sugars from those feedstocks (1/16)

 

Elusys
Therapeutics
Inc.*

U.S. Army Medical Research Institute of Infectious Diseases

CRADA

They extended agreement for R&D of therapeutics against anthrax and other biowarfare agents

The extension focuses on applying Elusys' HP Antibody technology as a platform for developing countermeasure agents (12/13)

 

Epiphany
Biosciences*

Columbia University

Licensing agreement

For the diagnostic  and therapeutic use of the KSHV/HHV-8 sequence and related patents

Epiphany previously had an exclusive option to the portfolio; KSHV or HHV-8 has been shown to cause serious and life-threat- ening disease such as cancer, especially in immuno compromised and HIV-positive patients (1/10)

 

Galapagos NV
(the Netherlands;
Euronext:GLPG)

The ALS AssociationTherapeutics Inc.

Collaboration

Galapagos will discover drug targets fordevelopment of drugs for amyotrophic lateral sclerosis

Galapagos may get up to $3M in  the deal; it also has an option todevelop certain resulting targets (12/11)

 

Galapagos NV
(the Netherlands;
Euronext:GLPG)

University of Bristol (UK)

Agreement

In the field of cancer research

Galapagos' service division, BioFocus DPI, will provide leadoptimization services for a university research program focusing on destroying cancer cells; total contract value exceeds €2M (US$2.6M) (2/15)

 

Genesis
Bioventures Inc.
(OTC BB:GBIW)

Firebird Global Master Fund II Ltd.

Investment

The investment comes in the form of a $0.5Mconvertible promissory note

Under the terms, the company will acquire rights to the Mammastatin therapeutic technology from the University of Michigan,and the company's subsidiary, Prion Developmental Laboratories, will begin production of the mad cow disease rapid assay teststrips (2/9)

 

GeneGo Inc.*

St. Jude Children's Research Hospital

Licensing agreement

For the data mining suite, MetaCore

MetaCore 4.2 includes a new ontology of cellular process networks, as well as additional functional processes and more genes have been networked using GeneGo network algorithms (1/30)

 

Genentech Inc.
(NYSE:DNA)

Walter and Eliza Hall Institute of Medical Research (Australia)

Exclusive global collaboration agreement

To discover, develop, manufacture and  commercialize a  new class of broad- spectrum cancer therapeutics

Genentech will make up-front and research program payments, with the possibility of milestone and royalty payments in the future (2/6)

 

GenPat77
Pharmacogenetics
AG*
(Germany)

Charite University of Medicine (Germany)

License agreement

GenPat got rights to an investigational cancer therapy, GP7.1

GP7.1 has been tested in a pilot study in patients with neuroblastoma; terms of the worldwide license were not disclosed (12/7)

 

GenVec Inc.
(GNVC)

Department of Homeland Security

Three-year contract

To support development and manufacture of adenovector- based vaccines against foot-and- mouth disease

Company will receive up to $6M in program funding the first year and up to $15M over three years (2/1)

 

GenVec Inc.
(GNVC)

Naval Medical Research Center

Collaboration

To conduct the first clinical study of a malaria vaccine  developed using the company's gene  delivery and cell culture manufacturing technologies

The technologies are used to produce recombinant adeno-virus vaccine vectors (1/17)

 

Gilead
Sciences Inc.
(GILD)

International Partnership for Microbicides and CONRAD

License agreement

IPM and CONRAD got certain rights to use of tenofovir as a microbocide

The nonprofits would be able to distribute the product in about 100 resource-limited countries  for preventing HIV (12/11)

 

HemoBioTech
Inc.
(OTC BB:HMBT)

Texas Tech University Health Science Center

Extended sponsored research agreement

To focus on commercial development of the company's HemoTech product as a substitute  for human red blood cells

HemoBioTech is paying about $780,000 to extend the agreement (2/1)

 

Illumina Inc.
(ILMN)

Children's Hospital of Eastern Ontario

Research collaboration

To develop molecular diagnostic tests to screen newborn babies for spinal muscular atrophy and hemoglobinopathies

Illumina and CHEO initially will develop assays to screen newborns using Illumina's VeraCode technology and BeadXpress reader (1/8)

 

Illumina Inc.
(ILMN)

Mayo Clinic

Collaboration

To co-develop molecular diagnostic tests for the study of complex diseases

Illumina will contribute its Vera- Code technology and development expertise for the BeadArray and BeadXpress instrument platforms; it will manufacture and market tests worldwide (1/10)

 

Introgen
Therapeutics
Inc.
(INGN)

University of Texas M.D. Anderson Cancer Center

License agreement

Introgen got worldwide rights to use INGN 241 (mda-7/IL-24) with several types of existing  therapies

Introgen is testing INGN 241 in Phase II and III cancer trials; terms of the deal were not disclosed(12/21)

 

KeyNeurotek AG*
(Germany)

Max Planck Innovation GmbH (Germany)

License agreement

To cover a method to identify drug candidates  at the Enzymology of Protein Folding research unit

Financial terms were not disclosed (2/15)

 

Lipomics
Technologies
Inc.*

University of California, Davis

Agreement

To collaborate on research projects  with an emphasis on personalized medicine

Lipomics will retain certain rights to develop diagnostic applications based on the data from the studies (2/27)

 

MacroGenics Inc.*

Juvenile Diabetes Research Foundation

Partnership

To support a pivotal multinational Phase II/III trial of teplizumab (MGA031)

The compound has shown promise in slowing the progression of Type I diabetes in children and adults newly diagnosed with the disease (1/3)

 

Medistem
Laboratories Inc.
(OTC BB:MDSM)

Rio Valley  Medical Clinic

Technology licensing and royalty  agreement

Any product derived from or involving infusion-quality adult stem cells

Medistem will receive a 90% royalty of the monthly net revenue in excess of $20,000 resulting from the clinic's sale of the products (1/5)

 

Mimetic
Solutions LLC*

University of Texas

Licensing agreement

For Affinimer  Chemistry

The technology allows for the creation of chemically engineered smart polymers that can bind specific "trigger" molecules and subsequently release a drug or other agent under preprogrammed conditions (3/7)

 

Novavax Inc.
(NVAX)

University of Massachusetts Medical School

Technology agreement

Novavax gained worldwide rights to a new virus-like particle technology

The technology uses paramyxo- viruses as a core for building a VLP vaccine; the agreement covers VLP vaccines for preventing any viral disease in humans (3/2)

 

Ovation
Pharmaceuticals
Inc.*

National Institute on Drug Abuse

CRADA

Five-year agreement to study the company's anticonvulsant product, vigabatrin, for cocaine  and methamphetamine dependence

Ovation and NIDA will jointly design and implement preclinical studies, as well as clinical trials (1/23)

 

PhytoMedical
Technologies Inc.
(OTC BB:PYTO)

Iowa State University

Sponsored research agreement

Expanded agreement regarding development of the company's  synthesized type A-1 polyphenolic compounds for Type II diabetes

The agreement allows for the continuation of research under a July 2006 agreement; the compounds are derived from cinnamon (3/7)

 

Poniard
Pharmaceuticals
Inc.
(PARD)

The Scripps Research Institute

Expanded research agreement

To include the  discovery of focal adhesion kinase inhibitors to treat cancer

Original agreement was signed in August 2005 and covered the discovery of small-molecule protein kinase inhibitors as therapeutic agents (1/10)

 

Presidio
Pharmaceuticals
Inc.*

Stanford University

Licensing agreement

To a hepatitis C virus technology

The technology is designed to target a specific region found in the HCV proteins NS4B and NS5A, viral proteins needed for virus replication (1/16)

 

Protein
Polymer
Technologies
Inc.
(OTC BB:PPTI)

University of Arizona

Materials transfer agreement

To provide genetically engineered protein polymers to the university

The university plans to design, fabricate and test the properties of protein-based biomaterials and scaffolds for applications in tissue engineering and regenerative medicine using PPTI's protein polymers (1/29)

 

pSivida Ltd.
(Australia; PSDV)

Faber Research LLC

License agreement

To develop pSivida's Durasert, Zanisert and Co-Drug drug delivery technologies for infectious disease and diseases of the ear

Faber will make $990,000 in payments to pSivida for the right to exclusively negotiate a licensing agreement for a period of three months and to fund the cost of a preclinical study (1/9)

 

ReNeuron Group
plc
(UK;
LSE:RENE)

Ludwig Institute of Cancer Research and  the Dana-Farber Cancer Institute

Revenue- sharing agreement

Concerns recently patented research  conducted by the  institutions on certain gene-based somatic cell expansion technology

ReNeuron is entitled to revenues based on a 1998 agreement (2/26)

 

Rexahn
Pharmaceuticals
Inc.
(OTC
BB:RXHN)

National Institute of Neurological Disorders  and Stroke Screening Program

Agreement

For the company's lead CNS compound, RX-10100, to be submitted to NINDS' Anticonvulsant

The program is focused on  discovery, optimization and development of drugs for epilepsy and other serious conditions (2/5)

 

RXi
Pharmaceuticals
(subsidiary of
CytRx Corp.;
CYTR)

University of Massachusetts Medical School

Expanded agreement

Companies signed a master agreement to provide RXi option rights to license all unrestricted therapeutic RNAi technology  developed at UMMS over the next three years

The license would be in return for cash payments and equity; option rights are contingent upon RXi's receipt of working capital funding in the coming months (1/16)

 

Sangamo
BioSciences
Inc.
(SGMO)

City of Hope

License agreement

Sangamo got exclusive rights to chimeric immunoreceptor tech- nology, which will be tested against cancers

They also will work to develop a cell therapy using the technology with Sangamo's zinc-finger tech ology; COH gets an up-front license fee and annual fees, and is eligible to get milestone and royalties payments (12/11)

 

Santhera
Pharmaceuticals
AG
(Switzerland;
SWX:SANN)

Translational Research in Europe- Assessment and Treatment of NeuroMuscular  Diseases

Collaboration

Santhera joined the TREAT-NMD network, which is coordinating research into rare neuromuscular diseases

TREAT-NMD is being funded by a five- ear, E10M European Union grant; it includes 21 academic  and commercial organizations in  11 European countries(11/29)

 

S*BIO Pte. Ltd.* (Singapore)

Department of Tumorbiology and Microbiology at the Karolinska Institute(Sweden)

Research collaboration

To evaluate the role of the company's histone deacetylase inhibitors

Researchers will evaluate the inhibitors in colorectal cancer and investigate the underlying  mechanisms of the development of gastrointestinal polyps and tumors (1/10)

 

S*BIO Pte. Ltd.*
(Singapore)

Agency for  Science, Technology and Research's Institute of Molecular and Cell Biology(Singapore)

Research collaboration

For the discovery and development of multiple oncology compounds

S*BIO will provide expertise in high- throughput screening, medicinal chemistry and the identification and optimization of lead compounds, while the institute will use its targets and assays to screen for chemical starting points (2/7)

 

Sequenom Inc.
(SQNM)

The Chinese University of Hong Kong

Exclusive rights agreement

For noninvasive prenatal diagnostic intellectual property

Sequenom also obtained exclusive rights to a portfolio of methylation and nucleic acid markers; financial terms were not disclosed (2/13)

 

SensiGen LLC*

University of Michigan

Exclusive license agreement

For a human papilloma-virus detection test developed at the university

The technology, called the Atto- Sense HPV Test, has demonstrated the ability to detect as few as one to three copies of HPV DNA in any blood or tissue sample, and also to clearly identify in a single assay each of the 15 unique genotypes of HPV that cause cervical cancer in women (2/22)

 

Sirtris
Pharmaceuticals
Inc.*

Massachusetts Institute of Technology

License agreement

Sirtris got exclusive rights to develop assay and gene therapy technologies using the SIRT1 gene

Sirtris will use the technology to further advance its sirtuin platform focused on therapeutics for diseases of aging; terms of the deal were not disclosed (11/30)

 

Stemagen*

University of Pennsylvania

Exclusive rights agreement

To a patent that covers a technique for the development of uniparental embryonic stem cells

Stemagen has created uniparental embryonic stem cell lines, which are derived from the  genetic material of an egg or sperm only, rather than a fertilized egg(3/5)

 

Stemline
Therapeutics Inc.*

Duke University, the British Columbia Cancer Agency and the Scott &  White Cancer Research  Institute

Exclusive, worldwide licensing agreement

For SL-401, a compound aimed at a cancer stem cell target

SL-401 is designed to target the interleukin-3 receptor, and early data demonstrated that it could impair the ability of cancer stem cells to form tumors (3/7)

 

Stratagene Corp.
(STGN)

Max Planck Innovation (Germany)

Co-exclusive license agreement

To more than 150 microRNA sequences

Stratagene will have the right to use the microRNA sequences for the development, manufacture and sale of molecular diagnostic

 

Trana
Discovery
Inc.*

Southern Research Institute

Collaboration

Deal to discover new classes of drugs for treating HIV

Trana will screen SRI's collection of nucleosides to discover anti-infectives that act through the inhibition of transfer RNA (12/13)

 

VASTox plc (UK;
LSE:VOX)

European Union

Research project

VASTox became a partner in the Targeting Cancer  Stem Cells for Therapy project

The company will work with five research organizations to develop treatments that target cancer stem cells; initial research will focus on leukemia and  breast cancer (1/17)

 

Waypharm SA*(France)

Cancer Research Technology Ltd. (UK)

Agreement

To license Thioplatin, a hypoxia- esponsive platinum-based cancer therapy

CRT granted Waypharm an exclusive six- month option to worldwide development and commercialization rights and will receive an up-front payment plus licensing fees, and milestone and royalty payments (2/5)

 

XDx Inc.*

University of Minnesota

Agreement

To exclusively license technology related to the use of gene expression to assess  the disease status of systemic lupus erythematosus patients

XDx and the university also  entered a deal with The FeinStein Institute that provides XDx access to SLE patient samples collected through an NIH-funded program to elucidate biomarkers of autoimmune diseases (2/20)

 

Xpention
Genetics Inc.
(OTC BB:XPNG)

University of Texas Health Science Center Immunological Test

Extended research agreement 

The extension through May 31, 2007, will permit the completion of a  project titled "Development of the p65 technology

It also will permit the continued collaboration with Margaret Hanausek, one of the co-inventors of the p65 technology (2/20)

 

Xytis Inc.*

National Institute of  Drug Abuse

CRADA

To further evaluate Neboglamine (XY2401) as a treatment for cocaine addiction

The company will test whether the antipscyhotic compound can help addicts abstain from the narcotic or prevent them from relapsing into addiction (1/8)

 

 
Notes:
 
This chart does not include grants or contract awards, or agreements between biotech companies and clinical
 
trial centers.
 
* Denotes privately held company.
 
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.
 
CRADA = Cooperative Research and Development Agreement.
 
Unless otherwise noted, shares are traded on the Nasdaq exchange.
 
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange.